


Apocynin

Cat. No.:	HY-N0088		
CAS No.:	498-02-2		
Molecular Formula:	C ₉ H ₁₀ O ₃		
Molecular Weight:	166.17		
Target:	NADPH Oxidase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (601.79 mM)
 H₂O : 3.33 mg/mL (20.04 mM); ultrasonic and warming and heat to 60°C
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	6.0179 mL	30.0897 mL	60.1793 mL
	5 mM	1.2036 mL	6.0179 mL	12.0359 mL
	10 mM	0.6018 mL	3.0090 mL	6.0179 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Apocynin is a selective NADPH-oxidase inhibitor with an IC₅₀ of 10 μM^{[1][2]}. Apocynin improves acute lung inflammation in Carrageenan (HY-125474)-induced pleurisy mice model^[3]. Apocynin can also be used for cancer research^[4]. Apocynin reverses the aging process in mesenchymal stem cells to promote osteogenesis and increases bone mass^[5].

In Vitro

Apocynin (100 μM; 1-7, 14 days) shows a significant increase in the expression level of an osteogenic marker in the aging

BMSCs after osteogenic induction^[3].

Apocynin (1, 10, 100 μ M, 0-48h) has selective inhibition the proliferation and adhesion to fibronectin of v-H-ras-transformed 3Y1 cells^[4].

Apocynin (1, 10, 100 μ M; 3, 6, 12 h) decreases the intracellular reactive oxygen species (ROS) level in HR-3Y1-2 but not 3Y1 cells. ^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:	Bone marrow stromal cells (BMSCs)
Concentration:	100 μ M
Incubation Time:	1-7,14 days
Result:	Increased the expression levels of the “stemness markers” Nanog and Oct-4. Decreased the expression levels of p53, p21 and p16 at both the mRNA level and protein level. Increased the expression of sox-2 and klf-4 by 82.4% and 38.7%, respectively, compared with the negative control group. Reduced the expression of NADPH oxidase by 66.5% compared with the negative control. Had no change in the cell cycle or proliferation. Ddecreased the percentage of SA- β –gal-positive (green-stained) cells was by 42.5%. Increased the expression levels of four pivotal osteogenic markers (Runx2, OSX, Ocn, and Col1).

Cell Proliferation Assay^[4]

Cell Line:	HR-3Y1-2, 3Y1 cells
Concentration:	0, 1, 10, or 100 μ M
Incubation Time:	48h
Result:	Inhibited the proliferation of HR-3Y1-2 but not 3Y1 cells at 10 μ M and 100 μ M.

RT-PCR^[3]

Cell Line:	HR-3Y1-2, 3Y1 cells
Concentration:	0, 1, 10, or 100 μ M
Incubation Time:	24, 36, 48 h
Result:	Selectively down-regulated 1-integrin cell surface expression on the HR-3Y1-2 cells. Decreased adhesion of HR-3Y1-2 cells to fibronectin-coated plates.

In Vivo

Apocynin (0.1 mg/kg/day, i.p., three times per week for 3 months) increases bone mineral density and total bone volume in SAMP6 mice^[3].

Apocynin (5 mg/kg, i.p.) reduces the degree of lung injury and attenuates the degree of acute inflammation in the Carrageenan (HY-125474)-induced pleurisy mice^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SAMP6 mouse model (Pharmacokinetic assay) ^[3]
Dosage:	0.1 mg/kg/day

Administration:	Intraperitoneal injection (i.p.), three times per week, for 3 months
Result:	<p>Showed a higher bone value and exhibited a lower percentage of SA-β-gal positive cells than the control group.</p> <p>Increased the expression of Ki67 and Oct-4 mRNA.</p> <p>Altered the osteoblast-osteoclast balance in bone and promoted the activity of osteoblasts.</p>
Animal Model:	Carrageenan (HY-125474)-induced pleurisy in male adult CD1 mice ^[5]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	<p>Blocked NADPH oxidase activation and attenuated neutrophil infiltration and lipid peroxidation in the lung tissue.</p> <p>Reduced the degree of PARP activation and the degree of IL-1β expression.</p> <p>Prevented carrageenan-induced IκB-α degradation and reduced the levels of NF-κB p65.</p> <p>Attenuated this iNOS expression, reduced the degree of positive staining for Fas ligand in the lung tissues.</p> <p>Inhibited cells apoptosis in carrageenan-treated mice.</p> <p>Prevented Bax expression and reduced the degree of positive staining for Bax.</p> <p>Attenuated carrageenan-induced inhibition of Bcl-2 expression and the loss of positive staining for Bcl-2 in mice subjected to carrageenan-induced pleurisy.</p> <p>Reduced the level of pERK1/2 and p38 expression.</p>

CUSTOMER VALIDATION

- Exp Mol Med. 2021 Sep;53(9):1307-1318.
- Redox Biol. 2018 May;15:418-434.
- Pharmacol Res. 2023 Nov 21:107009.
- Biomed Pharmacother. 2022 Jul;151:113098.
- Biomed Pharmacother. 2020 Jan;121:109615.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Sun J, et al. Apocynin suppression of NADPH oxidase reverses the aging process in mesenchymal stem cells to promote osteogenesis and increase bone mass. Sci Rep. 2015 Dec 21;5:18572.
- [2]. Yamasaki M, et al. Selective inhibition by apocynin of the proliferation and adhesion to fibronectin of v-H-ras-transformed 3Y1 cells. Biosci Biotechnol Biochem. 2012;76(6):1177-81.
- [3]. Impellizzeri D et al. Effect of apocynin, a NADPH oxidase inhibitor, on acute lung inflammation. Biochem Pharmacol. 2011 Mar 1;81(5):636-48.
- [4]. Stolk J, et al. Am J Respir Cell Mol Biol, 1994, 11(1), 95-102.
- [5]. Stefanska J, et al. Mediators Inflamm, 2008, 106507.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA